

Prescription Drug Prices public hearing agenda

Date/time: Thursday, Dec. 7, 2023, 1:30 p.m. to 4 p.m.

Location: Zoom webinar – <http://dcbspage.org/RXDRUGPRICEHEARING2023>.

You can also join by phone at 669-254-5252 (toll-free); ID: 161 321 0988.

Oregonians are encouraged to submit questions related to drug pricing and hearing topics or submit testimony on drug pricing. Once the meeting starts, members of the public can sign up to give testimony in the Zoom chat window.

Facilitator

- Andrew Stolfi (he/him), Oregon insurance commissioner, Department of Consumer and Business Services (DCBS) director

Moderators

- Sen. Deb Patterson (she/her)
- Rep. Christine Goodwin
- Rep. Cyrus Javadi
- Rep. Rob Nosse (he/him)

Agenda

Welcome and introductions – 1:30 to 1:40 p.m.

- Andrew Stolfi, insurance commissioner and DCBS director
- Ralph Magrish (he/him), Prescription Drug Affordability Board executive director, Division of Financial Regulation (DFR), DCBS

Program staff presentation – 1:40 to 2:10 p.m.

- Sofia Parra (she/her), program coordinator, Drug Price Transparency Program, DFR
 - Program overview
 - Trade secret claims and compliance efforts
 - Consumer reports
- Taran Heins (he/him), research analyst, Drug Price Transparency Program, DFR
 - Manufacturer reporting highlights from the drug price transparency annual report
- Numi Rehfield-Griffith (she/her), senior policy advisor, DFR, DCBS
 - Insurer reporting highlights from the drug price transparency annual report
 - Legislative policy recommendations

First public comment period – 2:10 to 2:20 p.m.

Sign up during the meeting to provide testimony or email rx.prices@dcbs.oregon.gov before the hearing.

First invited panel – 2:20 to 3:05 p.m.

Topic: Diabetic drugs approved for weight loss

- David Rind, MD (he/him), chief medical officer, Institute for Clinical and Economic Review
- Irvin M. Brown, Ed.D. (Black/African American, he/him), vice president Salem-Keizer NAACP, political action chair NAACP Alaska, Oregon, Washington
- Mihir Patel (he/him), PharmD, chief pharmacy officer, Regence Blue Cross Blue Shield of Oregon
- Charlie Fisher, OSPIRG state director

Second invited panel – 3:05 to 3:50 p.m.

Topic: What determines the cost of a generic and why are many so expensive?

- Michael Sargent, MPA, senior director, policy, Association for Accessible Medicines
- Dharia McGrew (she/her), Ph.D.; director, state policy, PhRMA
- Tonia Sorrell-Neal (she/her), senior director state affairs for Oregon, Taft-Hartley plan employer trustee, Pharmaceutical Care Management Association
- John Murray, RPh, Murrays Drugs, Heppner, Oregon

Second public comment period – 3:50 p.m. until end of hearing

Sign up during the meeting to provide testimony or email rx.prices@dcbs.oregon.gov before the hearing.

Notes

Members of the public who want to provide testimony can sign up after joining the Zoom meeting or email rx.prices@dcbs.oregon.gov before the hearing.

Questions and written testimony can be sent to rx.prices@dcbs.oregon.gov before or after the hearing.